Oct 21 (Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will continue to lead the contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk .
Maselli's open letter comes on the back of increased criticism regarding Novo Holding's acquisition of Catalent that could threaten competition in weight-loss drugs and cutting-edge gene therapies.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
((Leroy.Dsouza@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.